RecruitingPhase 4NCT05922124

Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii

Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)

Sponsor

Rambam Health Care Campus

Enrollment

734 participants

Start Date

Sep 1, 2024

Study Type

INTERVENTIONAL

Conditions

Carbapenem Resistant Bacterial Infection Acinetobacter Bacteremia Acinetobacter Pneumonia

Summary

Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will be compared to patients treated treated with colistin alone or colistin combined with meropenem.

Eligibility

Min Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ampicillin-sulbactam, a drug called Cefiderocol, and others for people with acinetobacter bacteremia, acinetobacter pneumonia, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 16 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCefiderocol

Test drug regimen

DRUGAmpicillin-sulbactam

Synergistic combination

DRUGColistin

Historical comparator

DRUGMeropenem

Historical comparator synergistic combination

Locations(3)

Rambam Health Care Campus

Haifa, Israel

Sheba Tel HaShomer Medical Campus

Ramat Gan, Israel

Shamir Medical Center (Assaf Harofeh)

Tel Aviv, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05922124

Related Trials

Optimising TREATment for Severe Gram-Negative Bacterial Infections

NCT0700404941 locations

Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units

NCT063925681 location

Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients

NCT062585512 locations